Webseiten-Bericht für agenusbio.com
Agenus: Better immunotherapies
Generiert am 28 März 2026 02:34 AM
Aktuelle Statistiken? UPDATE !
Der Wert ist 54/100
SEO Inhalte
Seitentitel
Agenus: Better immunotherapies
Länge : 30
Perfekt, denn Ihr Seitentitel enthält zwischen 10 und 70 Anzahl Zeichen.
Seitenbeschreibung
Activating the Power of the Immune System to Defeat Cancer
Länge : 58
Ideal, aber Ihre Seitenbeschreibung sollte zwischen 70 und 160 Zeichen (Leerzeichen incinbegriffen) enthalten. Benutzen Sie dieses kostenlose Werkzeug um die Länge zu prüfen.
Suchbegriffe
Nicht so gut. Wir konnten keine META-Suchbegriffe auf Ihrer Webseite finden. Benutzen Sie dieses kostenlose Werkzeug um META-Suchbegriffe zu erzeugen.
Og META Eigenschaften
Sehr gut, denn diese Webseite nutzt die Vorteile aus den Og Properties.
| Eigenschaft | Inhalt |
|---|---|
| type | website |
Überschriften
| H1 | H2 | H3 | H4 | H5 | H6 |
| 2 | 24 | 65 | 0 | 0 | 0 |
- [H1] Using Your Immune System to Defeat Cancer
- [H1] Using Your Immune System to Defeat Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
- [H2] Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab
- [H2] Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
- [H2] Innovative Immunotherapies
- [H2] Learn how our science is changing what’s possible
- [H2] Stage III MSS Colorectal Cancer
- [H2] Merkel Cell Carcinoma
- [H2] Undifferentiated Pleomorphic Sarcoma
- [H2] Bringing the Power of Immunotherapy to More Patients
- [H2] “30 years ago, we envisioned a future where the immune system could be harnessed to cure cancer. That vision remains our driving force today—science-led, patient-focused, and unwavering in our mission to transform outcomes.”
- [H2] In the News
- [H2] Get answers about clinical trials, patient access, and more
- [H2] By the Numbers
- [H3] OncoDaily
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
- [H3] Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
- [H3] Teaching the Immune System to Remember: Exclusive Conversation with Dr. Nicholas DeVito
- [H3] Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
- [H3] Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
- [H3] Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
- [H3] Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
- [H3] Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
- [H3] Redefining Cancer Care
- [H3] I never knew how close to this disease I would eventually become – Benny Johnson’s personal story with cancer
- [H3] Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status
- [H3] Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
- [H3] New bowel cancer treatment that shrinks tumours branded 'game-changing' giving hope to thousands
- [H3] Immunotherapies break into cold colorectal cancers at ASCO
- [H3] Royalty deals on the rise as Ligand takes stake in Agenus' success
- [H3] Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
- [H3] Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
- [H3] New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
- [H3] Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
- [H3] Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
- [H3] Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC
- [H3] New Strategies for Targeting CTLA-4 Emerge
- [H3] Immunotherapy in Metastatic Colorectal Cancer: More Than Just MSI-H?
- [H3] Activity of Botensilimab and Bastilimab in Advanced Ovarian Cancer
- [H3] Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
- [H3] New data give Agenus' combo drug another boost, this time in ovarian cancer
- [H3] Novel Immunotherapy Combination Shows Activity in Microsatellite-Stable Metastatic Colorectal Cancer
- [H3] Studies of novel therapeutic approaches highlighted during Colorectal Cancer Awareness Month at Dana-Farber
- [H3] Unpacking the Latest Research in Gastrointestinal Cancers
- [H3] Botensilimab and balstilimab in metastatic, pre-treated MSS-CRC
- [H3] Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
- [H3] Combo results may offer route back to approval for Agenus' unlucky cervical cancer drug
- [H3] Immunotherapy with two novel drugs shows activity in colorectal cancer
Bilder
Es konnten 164 Bilder auf dieser Webseite gefunden werden.
Bei 164 Bilder(n) fehlt ein ALT-Attribut. Fügen Sie ALT-Attribute zu Ihren Bildern, um die Bedeutung der Bilder für Suchmaschinen zugänglich zu machen.
Text/HTML Verhältnis
Anteil : 5%
Das Text zu HTML Code Verhältnis dieser Webseite ist niedriger als 15 Prozent, was bedeutet, dass Sie mehr Inhalte für Ihre Webseite schreiben sollten.
Flash
Perfekt, denn es wurde kein Flash auf Ihrer Webseite gefunden.
IFrame
Schlecht, denn Sie verwenden IFrames auf Ihrer Webseite, die von Suchmaschinen nicht indexiert werden können.
SEO Links
URL Rewrite
Gut. Ihre Links sind für Suchmaschinen gut lesbar (sprechende Links)!
Underscores in the URLs
Perfekt! Wir haben keine Unterstriche in Ihren Links entdeckt.
In-page links
We found a total of 41 links including 0 link(s) to files
| Anker | Typ | Natürlich |
|---|---|---|
| - | intern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| - | extern | natürliche Links |
| Opt-out preferences | intern | natürliche Links |
| Terms and Conditions of Use | intern | natürliche Links |
| Privacy Policy | intern | natürliche Links |
| Community Guidelines | intern | natürliche Links |
| Access to Investigational Medicines Policy | intern | natürliche Links |
| Report Adverse Event | intern | natürliche Links |
| Investor Portal | intern | natürliche Links |
SEO Suchbegriffe
Suchbegriffswolke
botensilimab access balstilimab patient news colorectal immunotherapy agenus cancer january
Keywords Consistency
| Suchbegriff | Inhalt | Seitentitel | Suchbegriffe | Seitenbeschreibung | Überschriften |
|---|---|---|---|---|---|
| cancer | 48 |  |
|
 |
|
| access | 29 | |
|
|
|
| botensilimab | 28 | |
|
|
|
| agenus | 25 | |
|
|
|
| colorectal | 23 | |
|
|
|
Benutzerfreundlichkeit
URL
Domain : agenusbio.com
Länge : 13
Favoriten Icon
Gut. Die Webseite hat ein Favicon.
Druckeigenschaften
Es konnten keine druckfreundlichen CSS-Angaben gefunden werden.
Sprache
Gut, denn Sie haben in den META-Elementen eine Sprache deklariert: en.
Dublin Core
Diese Webseite nutzt nicht die Vorteile der Dublin Core Elemente.
Dokument
Doctype
HTML 5
Verschlüsselung
Perfekt, denn Ihre Webseite deklariert einen Zeichensatz: UTF-8.
W3C Validität
Fehler : 0
Warnungen : 0
E-Mail Datenschutz
Achtung! Es wurde mindestens eine E-Mail Adresse im Klartext auf Ihrer Webseite gefunden. Benutzen Sie dieses kostenlose Werkzeug um E-Mail Adressen vor SPAM zu schützen.
Veraltetes HTML
Sehr gut! Sie verwenden aktuelle HTML Tags in Ihrem Webseitenquelltext.
Tipps zur Webseitengeschwindigkeit
|
Sehr gut, denn Ihre Webseite benutzt keine verschachtelten Tabellen. |
|
Schlecht, denn es wurden CSS-Angaben in HTML-Elementen entdeckt. Diese Angaben sollten in ein entsprechendes CSS-Stylesheet verlagert werden. |
|
Gut, denn Ihre Webseite enthält nur wenig CSS-Dateien. |
|
Nicht so gut, denn Ihre Webseite enthält viele Javascript-Dateien (mehr als 6). |
|
Gut! Sie nutzen die Vorteile von gzip. |
Mobile
Mobile Optimierung
|
Apple Icon |
|
META Viewport Tag |
|
Flash Inhalt |
Optimierung
XML-Sitemap
Perfekt! Ihre Seite hat eine XML-Sitemap.
| https://www.agenusbio.com/sitemap.xml |
Robots.txt
https://agenusbio.com/robots.txt
Sehr gut! Ihre Webseite enthält eine robots.txt-Datei.
Analytics
Fehlt
Wir haben nicht ein Analyse-Tool auf dieser Website installiert zu erkennen.
Webanalyse erlaubt die Quantifizierung der Besucherinteraktionen mit Ihrer Seite. Insofern sollte zumindest ein Analysetool installiert werden. Um die Befunde abzusichern, empfiehlt sich das parallele Verwenden eines zweiten Tools.
PageSpeed Insights
Gerät
Kategorien
Free SEO Testing Tool
Free SEO Testing Tool ist ein kostenloses SEO Werkzeug zur Analyse Ihrer Webseite